Concepedia

Paolo Orsini

PO

Statistics

Publications

38

Citations

2.5K

H-Index

26

Active since

1975

Affiliations

Nerviano Medical Sciences(Current)

University of Pisa

Scuola Normale Superiore

University of Cambridge

National Institute of Optics

Paolo Orsini is an author at Nerviano Medical Sciences specializing in drug discovery, pharmacology, and medicinal chemistry.

ORCID

Publications per year

1975–2025

38

Publications

38

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

, , +17

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

, , +17

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

R Bossi, Maria Beatrice Saccardo, Elena Ardini et al. · Biochemistry · 2010 · 167 citations

, , +17

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding

Paolo Pevarello, Maria Gabriella Brasca, Raffaella Amici et al. · Journal of Medicinal Chemistry · 2004 · 161 citations · Full text

, , +16

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

Gianluca Papeo, Helena Posteri, Daniela Borghi et al. · Journal of Medicinal Chemistry · 2015 · 143 citations · Full text

, , +13

1–5 of 38